MX2022015872A - Metodos y composiciones para prevenir diabetes tipo 1. - Google Patents

Metodos y composiciones para prevenir diabetes tipo 1.

Info

Publication number
MX2022015872A
MX2022015872A MX2022015872A MX2022015872A MX2022015872A MX 2022015872 A MX2022015872 A MX 2022015872A MX 2022015872 A MX2022015872 A MX 2022015872A MX 2022015872 A MX2022015872 A MX 2022015872A MX 2022015872 A MX2022015872 A MX 2022015872A
Authority
MX
Mexico
Prior art keywords
diabetes
compositions
methods
preventing type
diabetic subject
Prior art date
Application number
MX2022015872A
Other languages
English (en)
Inventor
Francisco Leon
Kevan C Herold
Sarah Alice Long
Peter S Linsley
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW110102871A external-priority patent/TW202146450A/zh
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of MX2022015872A publication Critical patent/MX2022015872A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En un aspecto, se proporciona un método para prevenir o retrasar la aparición de diabetes tipo 1 (T1D) clínica, que comprende: proporcionar un sujeto no diabético que está en riesgo de T1D; administrar una cantidad profilácticamente eficaz de un anticuerpo anti-CD3 al sujeto no diabético; y determinar, antes o después del paso de administración, que el sujeto no diabético tiene más de aproximadamente 5% a más de aproximadamente 10% de células T TIGIT+KLRG1+CD8+ en todas las células T CD3+, lo que es indicativo de prevención o retraso exitoso del inicio de T1D clínica.
MX2022015872A 2020-06-11 2021-06-11 Metodos y composiciones para prevenir diabetes tipo 1. MX2022015872A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063037968P 2020-06-11 2020-06-11
TW110102871A TW202146450A (zh) 2020-06-11 2021-01-26 用於預防第1型糖尿病的方法及組成物
US202163192242P 2021-05-24 2021-05-24
PCT/US2021/037039 WO2021252917A2 (en) 2020-06-11 2021-06-11 Methods and compositions for preventing type 1 diabetes
US17/345,495 US20220041720A1 (en) 2020-06-11 2021-06-11 Methods and Compositions for Preventing Type 1 Diabetes

Publications (1)

Publication Number Publication Date
MX2022015872A true MX2022015872A (es) 2023-05-16

Family

ID=78845926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015872A MX2022015872A (es) 2020-06-11 2021-06-11 Metodos y composiciones para prevenir diabetes tipo 1.

Country Status (9)

Country Link
US (1) US20220041720A1 (es)
JP (1) JP2023530109A (es)
KR (1) KR20230092863A (es)
AU (1) AU2021287998A1 (es)
BR (1) BR112022025381A2 (es)
CA (1) CA3182445A1 (es)
IL (1) IL298999A (es)
MX (1) MX2022015872A (es)
WO (1) WO2021252917A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2023230476A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
SG10201509588TA (en) * 2011-05-21 2015-12-30 Macrogenics Inc CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3

Also Published As

Publication number Publication date
WO2021252917A3 (en) 2022-01-20
KR20230092863A (ko) 2023-06-26
BR112022025381A2 (pt) 2023-01-24
CA3182445A1 (en) 2021-12-16
AU2021287998A1 (en) 2023-02-02
JP2023530109A (ja) 2023-07-13
IL298999A (en) 2023-02-01
US20220041720A1 (en) 2022-02-10
WO2021252917A2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
Herold et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years
MX2022015872A (es) Metodos y composiciones para prevenir diabetes tipo 1.
Kanamaru et al. Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells
Charmoy et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice
Prado et al. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity
i Líndez et al. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy
JOP20210298A1 (ar) طرق وتركيبات للوقاية من مرض السكري من النوع الأول
Liga et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen
JP2021006591A (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
Korneychuk et al. Interleukin 15 and CD4+ T cells cooperate to promote small intestinal enteropathy in response to dietary antigen
Sottile et al. HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
WO2005076965A2 (en) Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
JP2014510725A (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
Baeyens et al. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes
EP2062047B1 (fr) Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
Verastegui et al. Long-term immune dysfunction after radiotherapy to the head and neck area
Huang et al. Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation
Moonka et al. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation
EP0680336A1 (fr) Anticorps monoclonaux anti-lfa-1 pour la preparation d'un medicament destine a prevenir le rejet des greffes d'organes
Alijotas-Reig et al. Regulatory T cells, maternal–foetal immune tolerance and recurrent miscarriage: new therapeutic challenging opportunities
Chernyshov et al. Lack of soluble TNF‐receptors in women with recurrent spontaneous abortion and possibility for its correction
Vargas-Hernandez et al. Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations
JPWO2020171138A5 (es)
Ureshino et al. Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia
Mele et al. Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis